HRP20140588T1 - Spojevi kondenziranog prstena i njihova uporaba - Google Patents
Spojevi kondenziranog prstena i njihova uporaba Download PDFInfo
- Publication number
- HRP20140588T1 HRP20140588T1 HRP20140588AT HRP20140588T HRP20140588T1 HR P20140588 T1 HRP20140588 T1 HR P20140588T1 HR P20140588A T HRP20140588A T HR P20140588AT HR P20140588 T HRP20140588 T HR P20140588T HR P20140588 T1 HRP20140588 T1 HR P20140588T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- compound
- salt according
- optionally substituted
- substituents selected
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 12
- 150000003839 salts Chemical group 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- ZLUFAMFRKPKHHP-UHFFFAOYSA-N 2-[2-[7-ethoxy-5-(6-methylsulfonylpyridin-3-yl)oxy-1h-indol-2-yl]-4,5-dihydro-1,3-thiazol-5-yl]-n-methylacetamide Chemical compound C=1C=2C=C(C=3SC(CC(=O)NC)CN=3)NC=2C(OCC)=CC=1OC1=CC=C(S(C)(=O)=O)N=C1 ZLUFAMFRKPKHHP-UHFFFAOYSA-N 0.000 claims 1
- LRTULYJAJSFVNO-UHFFFAOYSA-N 2-[2-[7-methoxy-5-(6-methylsulfonylpyridin-3-yl)oxy-1h-indol-2-yl]-4,5-dihydro-1,3-thiazol-5-yl]-n-methylacetamide Chemical compound S1C(CC(=O)NC)CN=C1C1=CC2=CC(OC=3C=NC(=CC=3)S(C)(=O)=O)=CC(OC)=C2N1 LRTULYJAJSFVNO-UHFFFAOYSA-N 0.000 claims 1
- DQRMARZXJVOZIO-UHFFFAOYSA-N 2-methyl-1-[2-[5-(5-methylsulfonylpyridin-2-yl)oxy-7-propan-2-yloxy-1h-indol-2-yl]-4,5-dihydro-1,3-thiazol-5-yl]propan-2-ol Chemical compound C=1C=2C=C(C=3SC(CC(C)(C)O)CN=3)NC=2C(OC(C)C)=CC=1OC1=CC=C(S(C)(=O)=O)C=N1 DQRMARZXJVOZIO-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- -1 di-tert-butylphenylsilyloxy group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- UFEHBOZFLDKNJL-UHFFFAOYSA-N n-(2-hydroxy-2-methylpropyl)-2-[2-[7-methoxy-5-(6-methylsulfonylpyridin-3-yl)oxy-1h-indol-2-yl]-4,5-dihydro-1,3-thiazol-5-yl]acetamide Chemical compound C=1C=2C=C(C=3SC(CC(=O)NCC(C)(C)O)CN=3)NC=2C(OC)=CC=1OC1=CC=C(S(C)(=O)=O)N=C1 UFEHBOZFLDKNJL-UHFFFAOYSA-N 0.000 claims 1
- WMPGYLANWPSGGK-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-[2-[7-methoxy-5-(6-methylsulfonylpyridin-3-yl)oxy-1h-indol-2-yl]-4,5-dihydro-1,3-thiazol-5-yl]acetamide Chemical compound C=1C=2C=C(C=3SC(CC(=O)NCC(C)O)CN=3)NC=2C(OC)=CC=1OC1=CC=C(S(C)(=O)=O)N=C1 WMPGYLANWPSGGK-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000002769 thiazolinyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (12)
1. Spoj, naznačen time, da je predstavljen formulom (II):
[image]
gdje
prsten A je 6-člani prsten opcijski supstituiran, osim –W1-R1 i –W2-R2, s 1 do 3 atoma halogena;
prsten B je 5-člani ne-aromatski heterocikl koji sadrži dušik i opcijski je supstituiran s 1 do 3 supstituenta odabrana od sljedećih:
(1) C1-6 alkil-skupina opcijski supstituirana s 1 do 3 supstituenta odabrana od sljedećih:
(a) hidroksi-skupina,
(b) karbamoil-skupina opcijski mono- ili di-supstituirana sa supstituentima odabranima između sljedećih:
(i) C1-6 alkil-skupina opcijski supstituirana s 1 do 3 supstituenta odabrana iz hidroksi-skupine i C1-6 alkoksi-skupine, i
(ii) C3-10 cikloalkil-skupina,
(c) C1-6 alkoksi-skupina,
(d) karboksi-skupina,
(e) C1-6 alkoksi-karbonilna skupina,
(f) ne-aromatska heterociklička skupina, i
(g) ne-aromatska heterociklil-karbonilna skupina, i
(2) C1-6 alkoksi-karbonilna skupina; svaki od W1 i W je O;
R1 je C6-14 aril-skupina ili heterociklička skupina, od kojih je svaka opcijski supstituirana s 1 do 3 supstituenta odabrana od sljedećih:
(1) C1-6 alkilsulfonil-skupina, i
(2) C1-6 alkil-skupina opcijski supstituirana s 1 do 3 C1-6 alkoksi-skupine;
R2 je C1-6 alkil-skupina opcijski supstituirana s 1 do 3 supstituenta odabrana od sljedećih:
(1) C6-14 aril-skupina,
(2) aromatska heterociklička skupina opcijski supstituirana s 1 do 3 supstituenta odabrana između sljedećih:
(a) atom halogena, i
(b) C1-6 alkil-skupina,
(3) ne-aromatska heterociklička skupina,
(4) hidroksi-skupina,
(5) C1-6 alkoksi-skupina, i
(6) di-tert-butilfenilsililoksi- skupina;
i R3 je atom vodika, ili njegova sol.
2. Spoj ili sol prema zahtjevu 1, naznačen time, da prsten A je benzen.
3. Spoj ili sol prema zahtjevu 1, naznačen time, da 5-člani ne-aromatski heterocikl koji sadrži dušik u prstenu B je tiazolin.
4. Spoj ili sol prema zahtjevu 1, naznačen time, da je 2-[2-(7-metoksi-5-{[6-(metilsulfonil)piridin-3-il]oksi}-1H-indol-2-il)-4,5-dihidro-1,3-tiazol-5-il]-N metilacetamid.
5. Spoj ili sol prema zahtjevu 1, naznačen time, da je 2-(2-{7-(2-metoksi-1-metiletoksi)-5-[4-(metilsulfonil)hidroksi]-1H-indol-2-il}-4,5-dihidro-1,3-tiazol- 5-il)etanol.
6. Spoj ili sol prema zahtjevu 1, naznačen time, da je 2-metil-1-{2-[7-(1-metiletoksi)-5-{[5-(metilsulfonil)piridin-2-il]oksi}-1H-indol-2-il]-4,5-dihidro-1,3-tiazol-5-il}propan-2-ol.
7. Spoj ili sol prema zahtjevu 1, naznačen time, da je N-(2-hidroksi-2-metilpropil)-2-[2-(7-metoksi-5-{[6-(metilsulfonil)piridin-3-il]oksi}-1H-indol-2-il)-4,5-dihidro-1,3-tiazol-5-il]acetamid.
8. Spoj ili sol prema zahtjevu 1, naznačen time, da je 2-[2-(7-etoksi-5-{[6-(metilsulfonil)piridin-3-il]oksi}-1H-indol-2-il)-4,5-dihidro-1,3-tiazol-5-il]-N- metilacetamid.
9. Spoj ili sol prema zahtjevu 1, naznačen time, da je N-[2-hidroksipropil]-2-[2-(7-metoksi-5-{[6-(metilsulfonil)piridin-3-il]oksi}-1H-indol-2-il)-4,5-dihidro-1,3-tiazol-5-il]acetamid.
10. Farmaceutsko sredstvo, naznačeno time, da obuhvaća spoj ili sol prema zahtjevu 1.
11. Farmaceutsko sredstvo prema zahtjevu 10, naznačeno time, da se upotrebljava za profilaksu ili liječenje dijabetesa ili pretilosti.
12. Spoj ili sol prema zahtjevu 1, naznačen time, da se upotrebljava za profilaksu ili liječenje dijabetesa ili pretilosti.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008102691 | 2008-04-10 | ||
| PCT/JP2009/057625 WO2009125873A1 (en) | 2008-04-10 | 2009-04-09 | Fused ring compounds and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140588T1 true HRP20140588T1 (hr) | 2014-08-01 |
Family
ID=40671202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140588AT HRP20140588T1 (hr) | 2008-04-10 | 2014-06-23 | Spojevi kondenziranog prstena i njihova uporaba |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8673942B2 (hr) |
| EP (1) | EP2276760B1 (hr) |
| JP (1) | JP5528348B2 (hr) |
| KR (1) | KR20110002472A (hr) |
| CN (1) | CN102056924B (hr) |
| AR (1) | AR073609A1 (hr) |
| AU (1) | AU2009234666B2 (hr) |
| BR (1) | BRPI0910912A2 (hr) |
| CA (1) | CA2720686A1 (hr) |
| CO (1) | CO6321240A2 (hr) |
| CR (1) | CR11730A (hr) |
| CY (1) | CY1115247T1 (hr) |
| DK (1) | DK2276760T3 (hr) |
| DO (1) | DOP2010000301A (hr) |
| EA (1) | EA019640B1 (hr) |
| EC (1) | ECSP10010602A (hr) |
| ES (1) | ES2476265T3 (hr) |
| GE (1) | GEP20135846B (hr) |
| HK (1) | HK1152932A1 (hr) |
| HR (1) | HRP20140588T1 (hr) |
| IL (1) | IL208463A (hr) |
| MA (1) | MA32283B1 (hr) |
| ME (1) | ME01887B (hr) |
| MX (1) | MX2010011138A (hr) |
| MY (1) | MY152475A (hr) |
| NZ (1) | NZ588562A (hr) |
| PE (1) | PE20100734A1 (hr) |
| PL (1) | PL2276760T3 (hr) |
| PT (1) | PT2276760E (hr) |
| RS (1) | RS53378B (hr) |
| SI (1) | SI2276760T1 (hr) |
| UA (1) | UA104422C2 (hr) |
| UY (1) | UY32131A (hr) |
| WO (1) | WO2009125873A1 (hr) |
| ZA (1) | ZA201007682B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2371826A4 (en) | 2008-12-29 | 2012-06-27 | Takeda Pharmaceutical | NEW CONNECTION WITH CONDENSED RINGS AND ITS USE |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2014085486A2 (en) | 2012-11-30 | 2014-06-05 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin d metabolites |
| US9453038B2 (en) | 2012-12-17 | 2016-09-27 | Merck Sharp & Dohme Corp. | Glucokinase activator compounds, compositions containing such compounds, and methods of treatment |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05505612A (ja) | 1991-03-01 | 1993-08-19 | ハー・ルンドベック・アクティーゼルスカブ | 高血圧症及び末梢血管疾患の治療法 |
| US6506901B2 (en) * | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
| CN101103977A (zh) * | 2002-06-05 | 2008-01-16 | 株式会社医药分子设计研究所 | 糖尿病治疗药 |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| WO2006089397A1 (en) | 2005-02-22 | 2006-08-31 | Gemin X Biotechnologies Inc. | Methods for treating arthritis using triheterocyclic compounds |
| EP1873144B1 (en) * | 2005-04-20 | 2014-07-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US7799820B2 (en) * | 2005-09-30 | 2010-09-21 | Banyu Pharmaceutical Co., Ltd. | 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions |
| JP5260507B2 (ja) | 2006-10-19 | 2013-08-14 | 武田薬品工業株式会社 | インドール化合物 |
| WO2009025478A1 (en) * | 2007-08-17 | 2009-02-26 | Lg Life Sciences Ltd. | Indole and indazole compounds as an inhibitor of cellular necrosis |
| EP2220081A4 (en) * | 2007-12-20 | 2011-08-24 | Lg Life Sciences Ltd | GLUCCOAINEACTIVATORS AND THESE PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE SUBSTANCES |
| RU2460525C2 (ru) * | 2008-01-04 | 2012-09-10 | Эл Джи Лайф Сайенсиз Лтд. | Производные индола и индазола, обладающие консервирующим действием по отношению к клеткам, тканям и органам |
| EP2371826A4 (en) * | 2008-12-29 | 2012-06-27 | Takeda Pharmaceutical | NEW CONNECTION WITH CONDENSED RINGS AND ITS USE |
-
2009
- 2009-04-09 CA CA2720686A patent/CA2720686A1/en not_active Abandoned
- 2009-04-09 WO PCT/JP2009/057625 patent/WO2009125873A1/en active Application Filing
- 2009-04-09 SI SI200930911T patent/SI2276760T1/sl unknown
- 2009-04-09 PL PL09730930T patent/PL2276760T3/pl unknown
- 2009-04-09 ES ES09730930.6T patent/ES2476265T3/es active Active
- 2009-04-09 BR BRPI0910912-9A patent/BRPI0910912A2/pt not_active IP Right Cessation
- 2009-04-09 UA UAA201013332A patent/UA104422C2/uk unknown
- 2009-04-09 EA EA201071180A patent/EA019640B1/ru not_active IP Right Cessation
- 2009-04-09 US US12/936,785 patent/US8673942B2/en not_active Expired - Fee Related
- 2009-04-09 CN CN200980121846.8A patent/CN102056924B/zh not_active Expired - Fee Related
- 2009-04-09 MX MX2010011138A patent/MX2010011138A/es active IP Right Grant
- 2009-04-09 ME MEP-2014-66A patent/ME01887B/me unknown
- 2009-04-09 KR KR1020107025180A patent/KR20110002472A/ko not_active Application Discontinuation
- 2009-04-09 GE GEAP2009011998 patent/GEP20135846B/en unknown
- 2009-04-09 MY MYPI20104694 patent/MY152475A/en unknown
- 2009-04-09 EP EP09730930.6A patent/EP2276760B1/en active Active
- 2009-04-09 JP JP2010538248A patent/JP5528348B2/ja not_active Expired - Fee Related
- 2009-04-09 NZ NZ588562A patent/NZ588562A/en not_active IP Right Cessation
- 2009-04-09 AU AU2009234666A patent/AU2009234666B2/en not_active Ceased
- 2009-04-09 PT PT97309306T patent/PT2276760E/pt unknown
- 2009-04-09 RS RS20140324A patent/RS53378B/en unknown
- 2009-04-09 DK DK09730930.6T patent/DK2276760T3/da active
- 2009-09-18 AR ARP090103590A patent/AR073609A1/es unknown
- 2009-09-21 UY UY0001032131A patent/UY32131A/es not_active Application Discontinuation
- 2009-09-30 PE PE2009001166A patent/PE20100734A1/es not_active Application Discontinuation
-
2010
- 2010-10-04 IL IL208463A patent/IL208463A/en not_active IP Right Cessation
- 2010-10-08 DO DO2010000301A patent/DOP2010000301A/es unknown
- 2010-10-14 CR CR11730A patent/CR11730A/es unknown
- 2010-10-27 ZA ZA2010/07682A patent/ZA201007682B/en unknown
- 2010-11-01 MA MA33304A patent/MA32283B1/fr unknown
- 2010-11-10 CO CO10140654A patent/CO6321240A2/es active IP Right Grant
- 2010-11-10 EC EC2010010602A patent/ECSP10010602A/es unknown
-
2011
- 2011-07-05 HK HK11106909.4A patent/HK1152932A1/xx not_active IP Right Cessation
-
2014
- 2014-06-23 HR HRP20140588AT patent/HRP20140588T1/hr unknown
- 2014-07-02 CY CY20141100499T patent/CY1115247T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140588T1 (hr) | Spojevi kondenziranog prstena i njihova uporaba | |
| RU2454415C2 (ru) | Производное индола | |
| JP2010506825A5 (hr) | ||
| PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
| JP2010215644A5 (hr) | ||
| HRP20160678T1 (hr) | Derivati 2-(1,2,3-triazol-2-il)benzamida i 3-(1,2,3-triazol-2-il)pikolinamida kao antagonisti receptora oreksina | |
| PE20140207A1 (es) | Composiciones y metodos para modular el fxr | |
| RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| PE20141375A1 (es) | Activadores de glucoquinasa | |
| NZ589962A (en) | Inhibitors of stearoyl-CoA desaturase and uses thereof | |
| AR116394A2 (es) | Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
| PE20091201A1 (es) | AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| PE20120304A1 (es) | Derivados de 1,3-tiazolidina-2,4-diona con actividad sobre quinasas pim-1 y/o pim-2 y/o pim-3 | |
| JP2010540462A5 (hr) | ||
| NZ612544A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| ATE537169T1 (de) | Piperidin- und piperazinderivate als p2x3- antagonisten | |
| PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
| RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| EA201070592A1 (ru) | Ингибиторы пептиддеформилазы | |
| PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
| HRP20120240T1 (hr) | Piridil piperidin antagonisti receptora za oreksin | |
| HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
| HRP20100522T1 (hr) | Piridin karboksamidi kao inhibitori 11-beta-hsd1 |